http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer (PFE) Announces FDA Approves PENBRAYA
-
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
-
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
-
Pfizer (PFE) Announces FDA Approval of VELSIPITY for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
-
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
-
Pfizer (PFE) Announces FDA Approval of BRAFTOVI + MEKTOVI for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
-
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
-
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases
-
Pfizer Declares Fourth-Quarter 2023 Dividend
-
Ginkgo Bioworks (DNA) Announces Multi-Target RNA Discovery Collaboration with Pfizer (PFE)
-
Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
-
Pfizer (PFE) Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO for RSV
-
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
-
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE) and BioNTech (BNTX) Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
-
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
-
Pfizer (PFE) and Valneva (VALN) Report Positive Pediatric and Adolescent Phase 2 Booster Results
-
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
-
Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
-
European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV
-
Pfizer (PFE) Announces FDA Approval of ABRYSVO
-
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
-
Pfizer's (PFE) ELREXFIO Receives U.S. FDA Accelerated Approval for R/R Multiple Myeloma
-
Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
-
Busy earnings day, Meta reportedly prepares AI chatbot - what's moving markets
-
Arvinas (ARVN) and Pfizer (PFE) Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant
-
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed
-
Pfizer (PFE) Appoints Chris Boshoff as Chief Oncology Research and Development Officer
-
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy
-
Pfizer (PFE) Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
-
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
-
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
-
Pfizer (PFE) and Flagship Pioneering Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs
-
Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs
-
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
-
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
-
Pfizer (PFE) and OPKO (OPK) Announce FDA Approval of NGENLA
-
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
-
Pfizer (PFE) Announces FDA Acceptance of Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
-
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
-
Pfizer (PFE) to continue to progress on GLP-1-RA candidate for adults with obesity and type 2diabetes mellitus
-
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
-
FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
-
Pfizer Declares Third-Quarter 2023 Dividend
-
Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts
